Baxter slumps as Medical Products & Therapies drive Q2 revenue miss

21 hours ago 1

Earnings News
Healthcare
On the Move

Comments

BioNTech To Expand Vaccine Production At Baxter International Facility

Baxter International (NYSE:BAX) lost ~21% in the morning hours on Thursday to reach a new 52-week low as the healthcare product manufacturer fell short of the consensus with its Q2 2025 results, mainly due to weakness in its Medical

Recommended For You

More Trending News

Read Entire Article

Baxter slumps as Medical Products & Therapies drive Q2 revenue miss

Recommended For You

More Trending News

Related

Marcus & Millichap declares $0.25 dividend

MEA downplays tariff row, says India-US relationship built o...

Canfor Pulp Products reports Q2 results

MEA reports 1703 deportations of Indians from US in 2025

Middleby buys Frigomeccanica

Reinsurance Group of America declares $0.93 dividend

Tata Power Q1 Results: Net profit rises 9% to Rs 1,060 Crore...

T. Rowe Price Q2 earnings top consensus, helped by investmen...

IES Holdings Non-GAAP EPS of $3.95, revenue of $890M

Nvidia, Alphabet's CapitalG mull investment in Vast Data's n...

Telus says La Caisse to buy 49.9% interest in Terrion for $1...

Nexstar Media declares $1.86 dividend

Exxon tops Q2 expectations as higher production outweighs we...

Home Loan Calculation: How can you save Rs 21 lakh and 5 yea...

Roku stock down amid reduced Q2 margins

Cboe Global Markets beats top-line and bottom-line estimates...

Trump administration to trial Medicare, Medicaid coverage fo...

Top 3 Mutual Funds in India that gave highest returns over 5...

India's export loss due to higher US tariffs limited to 0.3 ...

10 finance companies that made the biggest leaps on the 2025...

Trending

Popular

صدور هشدار زرد هواشناسی در چهارمحال و بختیاری

تصویری پربازدید از مجسمه پاندای کونگ‌فو کار